Professor Deborah Ashby holds the Chair in Medical Statistics and Clinical Trials at Imperial College London, where she is also Co-Director of Imperial Clinical Trials Unit and Deputy Head of Imperial School of Public Health. Her research interests are in clinical trials, risk-benefit decision making for medicines, and the utility of Bayesian approaches in these areas. She has led the benefit-risk workstream of the IMI-funded PROTECT project, bringing together academic, pharmaceutical, regulatory and patient expertise to determine best practice, and innovate on both underpinning methods and communication of the benefits and risks of medicines.
Professor Ashby chairs the HTA Commissioning Board, and is Deputy Chair of the HTA Programme for the National Institute for Health Research, and is Chair of the Population Research Committee for Cancer Research UK. She was appointed as a member of the UK Commission on Human Medicines and regularly advises the European Medicines Agency. She was been elected to on the Council of the Royal Statistical Society, and has served as Senior Honorary Officer and Vice-President, and within the International Society of Bayesian Analysis she was elected to the Board of Directors and has served as Executive Secretary.
Prior to her appointment at Imperial, she held the Chair in Medical Statistics at Barts and the London School of Medicine and Dentistry, Queen Mary University of London and academic appointments at the University of Liverpool. She is a Chartered Statistician, and an Honorary Member of both the Faculty of Public Health Medicine and the Royal College of Radiologists. She was awarded the OBE for services to medicine in the 2009 New Years Honours List, was appointed an NIHR Senior Investigator in 2010, and elected to the Academy of Medical Sciences in 2012.
et al., 2016, Recommendations for benefit-risk assessment methodologies and visual representations, Pharmacoepidemiology and Drug Safety, Vol:25, ISSN:1053-8569, Pages:251-262
et al., 2016, Literature review of visual representation of the results of benefit-risk assessments of medicinal products, Pharmacoepidemiology and Drug Safety, Vol:25, ISSN:1053-8569, Pages:238-250
et al., 2015, Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Respiratory Medicine, Vol:3, ISSN:2213-2600, Pages:684-691
et al., 2014, Balancing benefit and risk of medicines: a systematic review and classification of available methodologies, Pharmacoepidemiology and Drug Safety, Vol:23, ISSN:1053-8569, Pages:667-678
et al., 2013, Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial, British Medical Journal, Vol:347, ISSN:1756-1833
et al., 2013, Emergency department treatments and physiotherapy for acute whiplash: a pragmatic, two-step, randomised controlled trial, The Lancet, Vol:381, ISSN:0140-6736, Pages:546-556
et al., 2009, Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease, JAMA - Journal of the American Medical Association, Vol:302, ISSN:0098-7484, Pages:37-48
et al., 2008, Internal and external validity of cluster randomised trials: systematic review of recent trials, British Medical Journal, Vol:336, ISSN:0959-8146, Pages:876-880
et al., 2008, Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study, British Medical Journal, Vol:336, ISSN:0959-8146, Pages:138-142
Ashby D, 2006, Bayesian statistics in medicine: A 25 year review, Statistics in Medicine, Vol:25, ISSN:0277-6715, Pages:3589-3631
et al., 2013, Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines